A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record

OBJECTIVE: Recently, the European Medicines Agency reported that strontium ranelate increases myocardial infarction risk in postmenopausal women, 8.5 years after it was registered for use in osteoporosis. Unreported serious adverse events in clinical trials for other pharmaceuticals have been descri...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolland, Mark J, Grey, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187454/
https://www.ncbi.nlm.nih.gov/pubmed/25293384
http://dx.doi.org/10.1136/bmjopen-2014-005787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187454/
https://www.ncbi.nlm.nih.gov/pubmed/25293384
http://dx.doi.org/10.1136/bmjopen-2014-005787

Ejemplares similares